Lipocine announces US FDA labelling changes for testosterone products: Salt Lake City Thursday, March 13, 2025, 16:00 Hrs [IST] Lipocine Inc., a biopharmaceutical company leveragi ...

A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment ...

Risk factors are things that change our likelihood of developing a disease. Factors that may increase our risk of developing vascular dementia include age, genetics, lifestyle, and other health ...

Lipocine (LPCN) announced that the FDA has recently informed sponsors of approved testosterone products about class-wide labeling changes. This ...

Accurate evaluation of retinal vascular networks at a micro-level could significantly improve our understanding of angiopathology and potentially aid ophthalmologists in disease assessment and ...

Background and aims In the primary prevention setting, low-dose aspirin reduces major vascular events (MVEs) by approximately ...

The following is a summary of "Engineering approach to study the effect of TEVAR on the cardiovascular system: A systematic ...

The National Consumer Disputes Redressal Commission recently directed a surgeon and a hospital to jointly and severally pay a ...

A free congenital heart disease screening camp for children between the ages of 0-18 years was held at District Hospital ...